Crescent Biopharma, Inc.

Stock Chart, Company Information, and Scan Results

$21.28(as of Apr 17, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Crescent Biopharma, Inc. Company Information, Fundamentals, and Technical Indicators

Stock Price$21.28

Ticker SymbolCBIO

ExchangeNasdaq

SectorHealthcare

IndustryBiotechnology

Employees44

CountyUSA

Market Cap$592.2M

EBIDTA-152.5M

10-Day Moving Average19.24

P/E Ratio-15.70

20-Day Moving Average16.95

Forward P/E Ratio0.00

50-Day Moving Average13.36

Earnings per Share-12.81

200-Day Moving Average12.90

Profit Margin-852.06%

RSI73.91

Shares Outstanding27.6M

ATR1.57

52-Week High29.00

Volume291,522

52-Week Low8.72

Most Recent Support Level19.05

Book Value203.0M

Most Recent Resistance Level20.68

Upper Keltner20.47

Lower Keltner13.42

Debt-to-Equity Ratio20.47

Next Earnings DateUnknown

Cash Surplus177.1M

Next Ex-Dividend DateUnknown

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.